Study S000707

A Thorough QTc Evaluation of the Effect of Liraglutide on Cardiac Repolarization in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled, Two Period Crossover Study Followed by Open-label Moxifloxacin (Positive Control) Administration

ClinicalTrials.gov record

Registration

Registration: NCT01516255
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 64
Start: 2006-07
Primary completion: 2006-11
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:placebo; DRUG:moxifloxacin; PROCEDURE:electrocardiogram (ECG)
Results posted: FALSE

Registered primary outcomes

Maximum time-matched mean difference between the baseline subtracted QTci intervals []

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024980	Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. Chatterjee DJ, Journal of clinical pharmacology	2009	Randomized trial	PMID 19737980 DOI	registry reference RESULT:19737980